Shang Hai Zheng Quan Bao·2026-02-06 19:24Investment Cooperation Overview - On December 22, 2025, the company approved a proposal for its subsidiary to invest in the Guangzhou Liwan Guangyao Venture Capital Fund, establishing a partnership with several entities to create the Guangzhou Liwan Guangyao Venture Capital Fund [2] - The partnership agreement was officially signed on December 31, 2025, with the fund's establishment aimed at enhancing investment scale and efficiency [2][3] Investment Progress - The Guangzhou Liwan Fund completed its business registration and obtained a business license on January 7, 2026, with a total initial capital contribution of 120 million yuan [3] - The fund was registered with the Asset Management Association of China on February 5, 2026, and received a private investment fund registration certificate [3] Impact on the Company - This investment aligns with the strategic direction of the company's second-phase fund, facilitating risk diversification and accelerating investment pace in innovative pharmaceuticals and high-end medical devices [4] - The company aims to transition from traditional business models to technology-driven development, laying a solid foundation for high-quality growth [4] Drug Consistency Evaluation - The company's subsidiary, Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd., received approval for its Alfacalcidol soft capsules to pass the consistency evaluation for generic drugs [5][6] - The product is used for treating calcium metabolism disorders and has a significant market presence, with sales figures indicating a competitive position [7] Financial Investment in Drug Development - Approximately 10.36 million yuan has been invested in the research and development of the Alfacalcidol soft capsules consistency evaluation project [7]